2025-04-14 15:08:55
Latest Post
IPO-bound Belrise Industries Ltd completes strategic acquisition of H-One India Private Limited
Mitsu Chem Plast Eyes ₹ 1,000 Cr Revenue by 2028
Aurobindo Pharma receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg
NHPC Ltd commissions commercial operation of 107.14 MW of 300 MW Karnisar Solar Power Plant
Nureca Limited's Manufacturing Subsidiary Secures US FDA Registration
Stock Report
Concord Drugs Ltd Q2FY22 net profit at Rs. 45.794 lakhs
Posted On : 2021-10-18 19:35:53( TIMEZONE : IST )
Concord Drugs Ltd has reported Standalone financial results for the period ended September 30, 2021.
Financial Results (Q2 FY2022) - QoQ Comparison
The company has reported total income of Rs. 9.8588 crores during the period ended September 30, 2021 as compared to Rs. 20.2410 crores during the period ended June 30, 2021.
The company has posted net profit / (loss) of Rs. 0.45794 crores for the period ended September 30, 2021 as against net profit / (loss) of Rs. 0.68770 crores for the period ended June 30, 2021.
The company has reported EPS of Rs. 0.52 for the period ended September 30, 2021 as compared to Rs. 0.79 for the period ended June 30, 2021.
| Financials | Q2 FY2022 | Q1 FY2022 | % Change |
| Total Income | ₹ 9.8588 crs | ₹20.2410 crs |  -51.29% |
| Net Profit | ₹0.45794 crs | ₹0.68770 crs | -33.41% |
| EPS | ₹0.52 | ₹0.79 | -34.18% |
Financial Results (Q2 FY2022) - YoY Comparison
The company has reported total income of Rs. 9.8588 crores during the period ended September 30, 2021 as compared to Rs.16.6116 crores during the period ended September 30, 2020.
The company has posted net profit / (loss) of Rs.0.45794 crores for the period ended September 30, 2021 as against net profit / (loss) of Rs.0.08066 crores for the period ended September 30, 2020.
The company has reported EPS of Rs.0.52 for the period ended September 30, 2021 as compared to Rs.0.092 for the period ended September 30, 2020.
| Financials | Q2 FY2022 | Q2 FY2021 | % Change |
| Total Income | ₹ 9.8588 crs | ₹16.6116 crs | -40.65% |
| Net Profit | ₹0.45794 crs | ₹0.08066 crs |  467.74% |
| EPS | ₹0.52 | ₹0.092 | 465.22% |
Financial Results (Half Year Ended FY2022) - YoY Comparison
The company has reported total income of Rs.30.0998 crores during the 6 Months period ended September 30, 2021 as compared to Rs.34.8364 crores during the 6 Months period ended September 30, 2020.
The company has posted net profit / (loss) of Rs.1.14564 crores for the 6 Months period ended September 30, 2021 as against net profit / (loss) of Rs.0.24607 crores for the 6 Months period ended September 30, 2020.
The company has reported EPS of Rs.1.31 for the 6 Months period ended September 30, 2021 as compared to Rs.0.281 for the 6 Months period ended September 30, 2020.
| Financials | Half Year Ended FY2022 | Half Year Ended FY2021 | % Change |
| Total Income | ₹30.0998 crs | ₹34.8364 crs | -13.60% |
| Net Profit | ₹1.14564 crs | ₹0.24607 crs | 365.57% |
| EPS | ₹1.31 | ₹0.281 | 366.19% |
Shares of Concord Drugs Ltd was last trading in BSE at Rs. 34.80 as compared to the previous close of Rs. 34.75. The total number of shares traded during the day was 16122 in over 137 trades.
The stock hit an intraday high of Rs. 36.00 and intraday low of 33.05. The net turnover during the day was Rs. 558088.00.
